- Conditions
- Gout and Hyperuricemia
- Interventions
- Empagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–20
of 20
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertension, Cardiovascular Diseases
- Interventions
- empagliflozin, Placebo tablet
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Diabetic Kidney Disease
- Interventions
- Finerenone 10 MG, Empagliflozin 10 MG
- Drug
- Lead sponsor
- Washington D.C. Veterans Affairs Medical Center
- Federal
- Eligibility
- 20 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Heart Failure
- Interventions
- Empagliflozin 10 mg, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- New Haven, Connecticut
- Conditions
- Diabetes Mellitus and Heart Failure
- Interventions
- LIK066, Placebo, Empagliflozin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 21
- States / cities
- Huntsville, Alabama • Carmichael, California • Concord, California + 18 more
- Conditions
- NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
- Interventions
- Lanifibranor, Placebo, Empagliflozin
- Drug
- Lead sponsor
- Inventiva Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 26
- States / cities
- Homewood, Alabama • Chandler, Arizona • Conway, Arkansas + 22 more
- Conditions
- Liver Cirrhosis, Cirrhosis, Ascites, Ascites Hepatic, Sodium-Glucose Transporter 2 Inhibitors
- Interventions
- Empagliflozin 10 MG
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Cardiovascular Diseases
- Interventions
- Empagliflozin, Placebos
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetes Mellitus, Type 2, Hypertension
- Interventions
- Empagliflozin low dose, placebo, Empagliflozin high dose
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 166 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 92
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 62 more
- Conditions
- Chronic Kidney Diseases, Pediatric Kidney Disease
- Interventions
- Empagliflozin 10 MG
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 12 Years to 25 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- End-stage Kidney Disease, Kidney Disease, Chronic, Dialysis, Diabetic, Non-diabetic, Kidney Dysfunction, Kidney Failure, Hemodialysis
- Interventions
- Empagliflozin, Placebo
- Drug · Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus Type 2
- Interventions
- Empagliflozin, Placebo
- Drug · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 64 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- PreDiabetes, Prediabetic State, Overweight and Obesity
- Interventions
- Empagliflozin, Multivitamin-Placebo
- Drug
- Lead sponsor
- Oregon State University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Corvallis, Oregon
- Conditions
- Chronic Kidney Disease, Type 2 Diabetes
- Interventions
- Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Temple, Texas
- Conditions
- Obesity, Vascular Health
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 30 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Prediabetes
- Interventions
- Empagliflozin 10mg daily, Lifestyle education
- Drug · Other
- Lead sponsor
- Charles George VA Medical Center
- Federal
- Eligibility
- 35 Years to 60 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Asheville, North Carolina
- Conditions
- Aging, Arterial Stiffness
- Interventions
- Empagliflozin 10 MG, Placebo
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 60 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Major Depressive Disorder
- Interventions
- Empagliflozin
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Acute Kidney Injury
- Interventions
- SGLT2 inhibitor
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Kidney Transplant; Complications, Diabetes Mellitus, Type 2
- Interventions
- Empagliflozin10Mg Tab, Placebo
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina